Key points
An opioid's potency shows how many times less of the drug by weight is needed for comparable relief than of morphine; the table sets out what is known about the strongest opioids and where they are used.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Acute pain after surgery, an intravenous pump the patient controls | pain relief on the level of morphine at a dose many times smaller by weight; the dose is in micrograms, so — only under supervision | network meta-analysis of 52 RCTs, 16 opioids: for comparable relief about 423 times less sufentanil was needed by weight than morphine, 58 times less fentanyl, 37 times less buprenorphine (PMID 36523208) |
| Tolerability: tapentadol | adverse events less frequent than with oxycodone | in systematic reviews the frequency of adverse events did not differ between opioids, with one exception — tapentadol shows a lower incidence than oxycodone; four pieces of work, the Cochrane review among them (French guideline 2026, PMID 42371399) |
| Long-lasting pain: fentanyl | almost a hundred registered names in the Italian register, mostly patches — a form for pain that lasts | — |
| Buprenorphine | patches are dispensed as an analgesic, sublingual forms as treatment for opioid dependence | — |
| Acute pain under supervision: sublingual sufentanil (Dzuveo) | authorised across the EU since 25 June 2018; prescription-only, given by a healthcare professional experienced in treating pain, in a monitored setting, for no more than 48 hours | — |
How it helps
The potency figures come from a network meta-analysis of 52 randomised trials covering 16 opioids (PMID 36523208).
| Drug | Times stronger than morphine | 95% CI |
|---|---|---|
| Sufentanil | 423 | 335–533 |
| Fentanyl | 58 | 48.2–68.6 |
| Buprenorphine | 37 | 26.7–50.8 |
| Remifentanil | 13 | 9.4–19.1 |
| Alfentanil | 7 | 4.0–11.0 |
| Hydromorphone | 6 | 5.0–8.4 |
| Morphine | 1 | — |
| Oxycodone | 0.9 | 0.65–1.34 |
| Tramadol | 0.08 | 0.07–0.10 |
All the data come from one device — a pump the patient operates. After surgery a person is given a button: the pain rises, they press, the machine delivers a dose intravenously and then locks for a set time.
The authors did something that makes the work worth reading: they refused to use existing conversion tables. Opioid potency is usually taken from reference tables that accumulated over decades and were copied from source to source. Instead, potency here was computed as the inverted ratio of total consumption — how much of the drug a person gave themselves before the pain settled to a comparable level.
Which gives a simple rule for reading the table: 423 for sufentanil means about 423 times less of it was needed by weight, not that it relieves pain 423 times better. The relief achieved across the compared trials was comparable; that was a condition of inclusion.
Tapentadol stands out for tolerability: in systematic reviews it is the one exception — adverse events are less frequent with it than with oxycodone (see «Key points»).
What potency means in practice
A difference in potency settles a question of dosing, not a question of choice.
When a drug is tens of times stronger than morphine, the work is done in micrograms rather than milligrams, and the cost of an arithmetic slip grows by the same factor. That is why the strongest opioids live where there is supervision, not in a bathroom cabinet.
The choice between drugs is decided by other things: how fast relief is needed, how long it must hold, the state of the kidneys and liver, what else the person is taking, whether they have had opioids before. The potency table answers none of those questions.
According to the systematic reviews cited by the French guideline, no significant differences in efficacy between opioid drugs were found — neither in pain relief nor in the recovery of daily function.
Where these drugs are used
The Italian medicines register shows where these drugs are actually used.
| Drug | Registered names | How it is supplied |
|---|---|---|
| Sufentanil | 4 | every pack hospital-only |
| Fentanyl | 95 | prescription, none over the counter; mostly patches |
| Buprenorphine | 71 | prescription; patches and sublingual forms serve different purposes |
The strongest drug on the list does not exist outside a hospital. Every registered sufentanil pack is classed for hospital supply. A sublingual form for use outside one did exist in Europe: Dzuveo was authorised across the EU on 25 June 2018 — and even that is prescription-only, given by a healthcare professional experienced in treating pain, in a monitored setting, and never for more than 48 hours. A second such product, Zalviso, had its authorisation withdrawn by the European Commission on 5 August 2022 at the request of the marketing authorisation holder, for commercial reasons.
Fentanyl has almost a hundred registered names, mostly patches — a form for pain that lasts, not for a shot on demand. Buprenorphine has split by purpose: patches are dispensed as an analgesic, sublingual forms as treatment for opioid dependence.
Who should see a doctor first
Opioid analgesics are used only as prescribed by a physician. The French national guideline on the appropriate use of opioids, published in August 2026 (PMID 42371399), says verbatim:
«Regardless of their pharmacological potency, the benefit–risk balance of opioid analgesics is primarily dose-dependent, with risks, including the development of opioid use disorder and overdose, shared across all opioids.»
France is among the least affected OECD countries for opioid mortality: an estimated 300–400 fatal overdoses a year, linked primarily to methadone (40%) and heroin (20%), with analgesic opioids far behind at 12%. For comparison, in the United States in 2017 opioids were implicated in two-thirds of 71,568 overdose deaths.
But to stop at that figure is to stop reading too early. The guideline's concern lies elsewhere: a new profile of the person who overdoses has appeared. Not the «typical» drug user, but someone opioid-naïve or an occasional user — someone whose dependence began with prescribed treatment.
That is why the sentence about dose matters more than the table about potency. The danger is not created by which opioid was prescribed, but by how much, for how long, and under what supervision.
Converting between forms and between drugs is a clinical task. The guideline states verbatim: there are no universally accepted opioid conversion tables for acute pain. The recommendation is to work from each drug's own product information, and when rotating from one opioid to another to reduce the calculated dose by 25–50%, because people respond to opioids differently and tolerance does not carry over completely between them.
Bottom line
The numbers in the table are real and were obtained by a good method — possibly the best available, because the authors declined to copy the old reference works and counted again from the trials.
One practical rule follows, and it runs against intuition: the higher a drug sits on the list, the less of it is needed and the less room there is for error. Potency is not might, it is scale. And where the scale is finer, supervision matters more.
Source: The Strongest Opioid Painkillers: What Potency Actually Means — universum.earth. Dr. Pereligyn.
